title: Comprehensive review of olopatadine: the molecule and its clinical entities.
abstract: Olopatadine is a tricyclic compound with antihistaminic, mast cell-stabilizing, and anti-inflammatory properties. In the United States olopatadine is approved as a b.i.d. ophthalmic solution, Patanol (Alcon Laboratories, Inc., Fort Worth, TX) to treat all signs and symptoms of allergic conjunctivitis and as a q.d. formulation, Pataday (Alcon Laboratories, Inc.), to treat itching associated with allergic conjunctivitis. A nasal spray, Patanase (Alcon Laboratories, Inc.), was approved in 2008 for treatment of the symptoms of seasonal allergic rhinitis. The available data on olopatadine was assessed with regard to future uses through a comprehensive literature review and a Roundtable Discussion held at the 2009 meeting of the American Academy of Allergy Asthma and Immunology. The unique mechanisms of action of olopatadine still under study include mast cell stabilization, potent H(1)-anthistaminic activity, and anti-inflammatory effects. Data support consideration of nasal olopatadine for as-needed use for episodic symptoms of allergic rhinitis, for treatment of nonallergic rhinitis, and for use in combination with topical steroids for patients with moderate-to-severe allergy symptoms.
authors.affiliation: Institute for Asthma and Allergy, Chevy Chase, Maryland 20815, USA. makaliner@aol.com
authors.forename: Michael A
authors.initials: MA
authors.lastname: Kaliner
authors.forename: John
authors.initials: J
authors.lastname: Oppenheimer
authors.forename: Judith R
authors.initials: JR
authors.lastname: Farrar
mesh_terms: D000486:Allergy and Immunology; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015550:Cell Degranulation / Q000187:drug effects; D002986:Clinical Trials as Topic; D003245:Consensus Statements as Topic; D003990:Dibenzoxepins / Q000494:pharmacology / Q000627:therapeutic use*; D004304:Dosage Forms; D004333:Drug Administration Routes; D017277:Drug Approval; D039563:Histamine H1 Antagonists, Non-Sedating / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D008407:Mast Cells / Q000187:drug effects*; D000069605:Olopatadine Hydrochloride; D012958:Societies, Scientific; D014481:United States
chemical_list: D000893:Anti-Inflammatory Agents; D003990:Dibenzoxepins; D004304:Dosage Forms; D039563:Histamine H1 Antagonists, Non-Sedating; D000069605:Olopatadine Hydrochloride